1 Result: CureVac
CureVac's Patent Litigation Moves to Virginia, Ambrx Biopharma Receives Overweight Rating, Legend Biotech Gets Price Target Boost
May 19th, 2023
CureVac N.V. (Nasdaq: CVAC) has made an important announcement regarding the ongoing patent litigation initiated by Pfizer (NYSE: PFE)/BioNTech (Nasdaq: BNTX). CureVac's motion to transfer the litigation from the federal district court of Massachuset. Read more
Want To Find Some News?
Recent Post
-
Honeywell, Intel, and Dover Earnings Preview: What to Expect
July 20th, 2025All Eyes on Tesla, ServiceNow, and GE Vernova Ahead of Earnings
July 20th, 2025RTX, Texas Instruments, and Northrop Grumman Earnings in Focus
July 20th, 2025
Member Login